Sanofi's MenQuadfi gains EU approval for infants from six weeks, broadening meningococcal vaccine reach

Sanofi’s MenQuadfi has received European approval for use in infants from six weeks old, expanding protection against invasive meningococcal disease and marking a significant milestone in early childhood immunisation efforts. Sanofi has said MenQuadfi has won European approval for use…













